Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate
  • Clinical Data

Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate

BioSpace

If Biogen has shown that tau can impact cognition, Denali's technology--validated with an FDA approval in Hunter syndrome--could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

pharminent May 15, 2026

BioSpace

If Biogen has shown that tau can impact cognition, Denali’s technology–validated with an FDA approval in Hunter syndrome–could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Genmab drops 2 antibody assets, including another ProfoundBio ADC
Next: ECO 2026: tirzepatide shows potential for T1D treatment

Related Stories

  • Clinical Data

Pfizer drug acquired in Seagen deal disappoints in lung cancer study

pharminent June 23, 2026
  • Clinical Data

Boehringer advances duo for aggressive cancers into phase 3

pharminent June 22, 2026
  • Clinical Data

Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short

pharminent June 17, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.